Strong Third Quarter 2025 Performance
Johnson & Johnson (JNJ) concluded the third quarter of 2025 with strong financial results, reporting a 6.8% year-over-year revenue growth to $24 billion and a 16% increase in adjusted earnings per share (EPS) to $2.80. This performance has led the company to raise its full-year 2025 revenue guidance midpoint to approximately $93.2 billion, while maintaining its adjusted EPS guidance at approximately $10.85. The company's stock has demonstrated resilience, gaining 30.6% year-to-date and 17.6% over the past 52 weeks, outperforming the S&P 500 Index ($SPX) and the Health Care Select Sector SPDR Fund (XLV).
Pharmaceutical Portfolio Expansion and Regulatory Successes
The quarter was significantly marked by strategic expansions within Johnson & Johnson's pharmaceutical portfolio, particularly in oncology and neuroscience, underscored by recent U.S. Food and Drug Administration (FDA) approvals. On November 6, 2025, the FDA approved Caplyta (lumateperone) as an adjunctive therapy for major depressive disorder (MDD) in adults. This approval, the first under J&J's leadership following its acquisition of Intra-Cellular Therapies, is anticipated to unlock a substantial, underserved market. Analysts from Leerink Partners estimate that entering the MDD market could add at least $1 billion to Caplyta's sales, with J&J itself projecting $5 billion in annual sales eventually. In 2024, Caplyta generated $680 million in sales. This expansion builds on the success of Spravato (esketamine), which recorded $1 billion in annual sales in 2024 and $1.19 billion in the first nine months of 2025.
In oncology, Johnson & Johnson secured FDA approval for INLEXZO for BCG-unresponsive non-muscle invasive bladder cancer. This adds to an already robust oncology pipeline, which saw DARZALEX FASPRO's expanded FDA indication. A significant contributor to growth was CARVYKTI, which achieved $524 million in worldwide sales, representing an 83.5% year-over-year increase from $286 million in the same period in 2024. Furthermore, the publication of Phase 3 MARIPOSA study results, revealing significant survival improvements with RYBREVANT plus LAZCLUZE in EGFR-mutated non-small cell lung cancer, highlights the company's innovation focus and potential to influence future oncology treatment standards.
Strategic Acquisitions and Financial Outlook
The acquisition of Intra-Cellular Therapies is a pivotal component of Johnson & Johnson's strategy to bolster its neuroscience leadership. This transaction is expected to accelerate 2025 sales growth by approximately 0.8%, contributing an estimated $0.7 billion in incremental sales. While the acquisition is projected to dilute adjusted EPS by approximately $0.25 in 2025 (an improvement from the initial estimate of $0.30–$0.35), this dilution is expected to reduce to approximately $0.21 per share in 2026, as annualized financing costs are partially offset by operational accretion. Beyond Caplyta, the acquisition includes ITI-1284, a promising Phase 2 compound for generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation, further complementing Johnson & Johnson's existing areas of focus.
Market Reception and Analyst Perspectives
The market has responded positively to Johnson & Johnson's consistent performance and strategic initiatives. The JNJ stock's year-to-date gain of 30.6% notably surpasses the S&P 500 Index's 16.3% increase and the Health Care Select Sector SPDR Fund's 4.9% rise over the same period. Analyst sentiment remains largely bullish, with 13 out of 25 analysts issuing a “Strong Buy” rating, two a “Moderate Buy,” and ten a “Hold” rating for JNJ stock. These ratings reflect confidence in the company's robust pipeline, successful product launches, and strategic market positioning.
Future Outlook and Key Considerations
Looking ahead, Johnson & Johnson is poised for continued growth, driven by its innovative pharmaceutical pipeline and strategic acquisitions. The company's outlook forecasts $104.1 billion in revenue and $22.9 billion in earnings by 2028. Key factors to monitor include the ongoing execution of its pipeline, particularly in oncology and neuroscience, and its ability to effectively navigate potential biosimilar competition, which remains a principal risk. The recent FDA approvals and the integration of Intra-Cellular Therapies are critical steps in offsetting potential patent expiries and strengthening the Innovative Medicine segment. The continued commercial success of drugs like Caplyta, Spravato, and CARVYKTI will be instrumental in achieving these long-term financial targets.
